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Flubendazole (FLU), a benzimidazole anthelmintic drug with a broad spectrum 
of activity and low toxicity has been used in veterinary as well as human medicine 
for a long time. Owing its mechanism of action, based on the specific binding to tubulin, 
FLU is now considered a promising anti‐cancer agent. However, we do not have enough 
information about its biotransformation in human.  
In our project, subcellular fractions from the liver of 12 human patients (6 males 
and 6 females) were used to study the stereospecificity, cellular localization, coenzyme 
preference and possible inter-individual or sex differences in FLU reduction. In addition, 
the risk of FLU interaction with other drugs was evaluated. Results showed that FLU is 
predominantly reduced in cytosol and the NADPH coenzyme is preferred. The strict 
stereospecificity of FLU carbonyl reduction was proven and carbonyl reductase 1 was 
identified as the main enzyme of FLU reduction in the human liver. A higher reduction 
of FLU and a higher level of carbonyl reductase 1 protein was found in males than 
in females, but overall inter-individual variability was relatively low. Hepatic intrinsic 
clearance of FLU is very low, and FLU had no effect on doxorubicin carbonyl reduction 
in the liver and in cancer cells. For these reasons, interactions of FLU with other carbonyl 
bearing drugs are not expected. The obtained results demonstrate the safety of FLU use 
in human and support FLU repurposing for cancer treatment. 
 
